The past decade of research has seen considerable interest in computer-based approaches designed to directly target cognitive mechanisms of anxiety, such as attention bias modification (ABM).
INTRODUCTION
Anxiety disorders are characterized by altered information processing patterns, including preferential allocation of attention toward threatrelevant information (henceforth, "attentional bias"; AB). Biased attention toward disorder-relevant cues is a highly transdiagnostic construct, present across a very wide range of psychopathology spanning internalizing and externalizing conditions [e.g., anxiety (Bar-Haim, Lamy, Pergamin, Bakermans-Kranenburg, & van IJzendoorn, 2007) , depression (Peckham, McHugh, & Otto, 2010) , trauma (Naim et al., 2014) , suicidality (Cha, Najmi, Park, Finn, & Nock, 2010) substance use (Waters, Marhe, & Franken, 2012) , abuse perpetration (Smith & Waterman, 2004) , unhealthy eating (Calitri, Pothos, Tapper, Brunstrom, & Abbreviations: AB, attentional bias; ABM, attention bias modification; RT, attentional bias Rogers, 2010) ]. Patterns of AB also appear fairly well preserved across the life span; for instance, anxious individuals from pediatric to geriatric (Mohlman, Price, & Vietri, 2013; Price, Siegle, & Mohlman, 2012) samples show similar patterns of AB. Broadly, modifying the focus of attention is a core feature or posited mechanism of treatments as diverse as cognitive-behavioral therapy, Eastern meditation practices, and serotonergic medications (Harmer, Goodwin, & Cowen, 2009) , suggesting a possible common pathway to symptom relief.
The past decade has seen growing interest in the development of automated, mechanistic treatments designed to modulate attentional patterns directly (MacLeod & Clarke, 2015) . Such interventions take advantage of technology to increase patient access, reduce (e.g., anxiety), hypervigilance toward negative information is seen as a key factor in the etiology and maintenance of affective dysfunction.
Initial data strongly supported a causal role for AB in contributing to anxiety vulnerability (MacLeod, Rutherford, Campbell, Ebsworthy, & Holker, 2002) and the therapeutic potential of attention bias modification (ABM) interventions in clinical populations (Amir, Beard, Burns, & Bomyea, 2009; Amir, Beard, Taylor, et al., 2009 ). However, more recent studies have lessened enthusiasm, reporting null or clinically insignificant effects (e.g., Beard, Sawyer, & Hofmann, 2012; Carlbring et al., 2012) . Critically, the extant literature suggests that if and when interventions are effective in modulating attentional patterns, symptoms are reduced in turn (Clarke, Notebaert, & Macleod, 2014; MacLeod & Clarke, 2015; Price, Wallace, et al., 2016) . Thus, the mechanistic target itself-AB-has been well validated, while the ability to manipulate the target remains inconsistent, hindering clinical translation.
The current study extends a prior meta-analytic report where we used a pooled patient-level meta-analysis approach (Price, Wallace, et al., 2016) . We compiled raw, per-patient data from randomized controlled trials of ABM, administered to adults with elevated levels of anxiety (according to clinical diagnosis or symptom scale distributions).
This approach offers unique advantages over standard meta-analytic techniques, including an order of magnitude increase in data points analyzed on each variable (many per study rather than one summary measure per study)-which substantially increases power, particularly for testing moderators and mediators (Riley, Lambert, & Abo-Zaid, 2010 )-and the ability to test hypotheses not reported in original studies. Our previous report suggested that ABM is efficacious in reducing clinical symptoms under specific circumstances-namely, for patients who were younger (≤37 years), trained in the laboratory (rather than at home/via Internet), and/or assessed by clinicians (rather than via self-report). Furthermore, our mediational analyses supported posited mechanistic links between AB and anxiety reduction, validating ABM's theoretical basis by suggesting ABM exerts effects on anxiety via its target mechanism. However, we previously focused narrowly on a constrained set of a priori hypotheses and did not assess the influence of additional design decisions made by investigators. Here, we aimed to leverage this unique dataset to answer a simple yet critical question that faces every researcher or clinician wishing to apply ABM to a clinical population: how many trials (repetitions) of ABM are optimal to achieve symptom reduction?
In examining this question, previous standard (study-level) metaanalyses have typically quantified dose as the number of discrete sessions of training given. However, learning opportunities both within and between sessions are important in ABM Abend, Pine, Fox, & Bar-Haim, 2014) , which can be quantified succinctly by calculating the total number of training trials given (i.e., number of sessions × training trials/session). Only one previous metaanalysis explored the impact of dose specifically among clinical intervention studies, and failed to reveal significant effects of dose on clinical anxiety symptoms (Heeren, Mogoase, Philippot, & McNally, 2015) .
Meta-analyses combining clinical and nonclinical samples have also sought to address this question, but these analyses typically include many studies where only a single session of ABM is given (in contrast to clinical intervention studies, where some degree of cross-session repetition is assumed to be critical, and almost always included), and have also sometimes combined diverse forms of cognitive bias modification (e.g., ABM and interpretation bias training) and clinical measures (depression, anxiety), complicating interpretation. When examining dose as a potential moderator, these meta-analyses in combined (clinical + nonclinical) samples have reported quite mixed results, ranging from no significant moderating effect on anxiety measures (Hakamata et al., 2010; Mogoaşe, David, & Koster, 2014) , to an enhanced effect of ABM on subjective posttraining outcomes when more sessions are given (Beard et al., 2012) , to equivocal findings driven by a binary distinction for single versus multiple sessions (Hallion & Ruscio, 2011) , to a paradoxical inverse relationship between number of sessions and clinical measures (Cristea, Kok, & Cuijpers, 2015) . Thus, meta-analyses to date have failed to resolve the crucial question of how to optimize ABM dose in order to achieve maximal clinical benefit. We sought to address this fundamental question with increased power and precision in our pooled patient-level dataset, focusing on a precise quantification of dose (total number of training trials), one specific intervention (dot-probe-based ABM), and one specific, clinical outcome (social anxiety symptoms).
METHODS

Study identification and selection
All details of the meta-analytic methods have been described previously (Price, Wallace, et al., 2016) . The meta-analytic protocol was preregistered at: http://www.crd.york.ac.uk/PROSPERO/ (CRD420 15019558). Briefly, PubMed, PsychINFO, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched over the period 01/01/2002-05/01/2015 using search terms and synonyms representing ABM ("attention* bias modification," "attention* *training, " "ABM") and anxiety ("anxiety"/exp, anxi*). A stand-alone ABM intervention was required, defined as any automated procedure designed to directly alter attention toward threat. A randomized controlled trial design was required to minimize bias. Allowable control conditions included sham or inverse (toward threat) variants of the same computer task. A constraint in patient-level meta-analysis is the use of uniform outcome measures, as there is no validated method to put individual patient scores, obtained on nonidentical scales, into the same "space, " and the assumptions that would be required to standardize disparate scales (e.g., that all scales measure the same construct; that all studies had a similar distribution of scores across their full sample) were deemed statistically inappropriate. Thus, for the dataset analyzed here, the use of the Liebowitz Social Anxiety Scale (LSAS) as an outcome was required (in either clinician-rated or self-report format, which are identical questionnaires producing highly convergent scores (Fresco et al., 2001) ), as the literature review revealed this was the most commonly used anxiety outcome measure among otherwiseeligible studies. Finally, to measure ABM's target mechanism (AB) using reasonably uniform procedures, a dot-probe task (described below) was required at the start and end of the intervention (either as a distinct pre/posttraining assessment, or as a first and last ABM training session; see details below). Raw trial-by-trial reaction time (RT) and accuracy data were requested for each participant to allow uniform methods to be applied in calculating AB indices [see (Price, Wallace, et al., 2016) ]. In cases where trial-level data were not retained, precalculated AB scores per-participant were requested. Of 13 eligible studies, 11 studies (Table 1) contributed at least one endpoint. See (Price, Wallace, et al., 2016) for study quality assessments and additional methodological details.
AB assessment and modification
In the dot-probe task, a widely-used RT measure of AB (MacLeod, Mathews, & Tata, 1986) , two stimuli are presented simultaneously (one threat-related and one comparison-typically neutral or positive).
After a specific interval (e.g., 500 ms), both items are removed and a neutral "probe" appears in one of the two locations. The probe (but not the neutral/threat images that preceded it) requires a response (e.g., indicate via button press whether the letter "E" or "F" is shown).
In "incongruent" trials, the probe replaces the nonthreat item in the pair, while in "congruent" trials, the probe replaces the threat item. AB toward threat is inferred when an individual's mean RT to incongruent trials is longer than the mean RT to congruent trials, suggesting attention was more likely to be allocated toward the threat cue location at the moment the probe appeared.
All studies in the current analysis used a training variant of the dot-probe as the ABM intervention (MacLeod et al., 2002) . Although this was not explicitly required by inclusion/exclusion criteria, the dotprobe approach to ABM has been predominant in the literature to date.
Only two studies meeting most of the eligibility criteria were found during the literature review that used alternate automated training procedures, and these were excluded because they did not include a dot-probe assessment measure (prohibiting pooling with other studies to test hypotheses regarding AB).
In the ABM variant of the dot-probe, the probe replaces the less threatening item in the stimulus pair with greater likelihood than the threat-related item, systematically drawing attention away from threat. Typically, sessions are ≤20 min and involve minimal-to-no contact with personnel. All contributing studies included a sham control group which completed an identical task, except that there was no systematic contingency regarding the probe location (probes appeared with equal likelihood in the threat or nonthreat location). A subset of studies included an additional control group: inverse training drawing attention toward threat (three studies; see Table 1 ). The modal stimulus type was facial expressions, with only two exceptions (see Table 1 ).
All but one study incorporated 500 ms presentations (although two of these studies began with 1,000 ms presentations for the first half of each session), while a single study utilized subliminal (17 ms) presentations (i.e., presentation times too brief to be consciously perceived).
Dosing
The methods sections of contributing studies were reviewed by two independent raters to extract the total number of training trials/repetitions delivered across the course of all sessions in the experiment (i.e., number of training trials/session × total number of sessions; see Table 1 ). Interrater reliability was 100%. Within each study, dosing was always equivalent for the ABM and control conditions. Only per-protocol completers were included in analyses (94% of all randomized participants), ensuring all participants received the full intended dose. Due to the small number of studies and overrepresentation of studies using certain specific dosing parameters (e.g., 1,280 trials; see Table 1 ), primary analyses used a dichotomized dosing variable based on a median split. Median splits are robust and can enhance power given an uneven, skewed, or suboptimal linear distribution, and also provide a parsimonious and readily interpretable cutpoint for practical decision making (Iacobucci, Posavac, Kardes, Schneider, & Popovich, 2015) . Secondary analyses utilized continuous numerical dose values to assess for convergence of findings across analytic strategies.
Statistical analysis
Analyses were first conducted comparing ABM versus all control conditions (collapsed into one group); follow-up analyses compared ABM to specific control conditions (sham and inverse training). Predictors were as follows: treatment condition, dose (dichotomized or continuous), and their interaction. Outcomes were as follows: posttraining LSAS score (covarying pretraining LSAS) and posttraining AB (covarying pretraining AB). One-step individual patient data analyses (Riley et al., 2008) were completed using linear mixed effects regression models, including a random study effect to account for clustering within study. Patient-level data were considered level 1 and study-level data were considered level 2. Analyses were performed using R version 3.1.
RESULTS
ABM versus all control groups
LSAS
There was a significant moderating effect of dose [dichotomized as ≤1,280 trials, producing seven "low dose" (N = 348) and four "high 
AB
There was a similar significant moderating effect of dose (dichotomized: four "low dose" (N = 159) and four "high dose" studies (N = 297)]) on posttraining AB [dose × treatment = 13.90; P = .020; Fig. 2 ABM, attention bias modification; AB, attention bias; LSAS, Liebowitz Social Anxiety Scale; SR, self-report; CR, clinician-rated; N, number randomized. All studies contributing data used a dot-probe task for ABM intervention.
a Stimulus presentation times for ABM and control training were 500 ms unless otherwise noted.
b Study did not administer standard ABM away from threat. Data from sham and inverse training groups were used to aid power and precision of estimates for control conditions. No findings were altered excluding this study. 
Sensitivity analyses 3.2.1 ABM versus specific control groups
Sensitivity analyses were conducted to assess whether observed dos- Table 2 shows that dose did not appear to be confounded with other possible explanatory variables, including other known moderators of posttraining LSAS in this meta-analytic sample (Price, Wallace, et al., 2016) . Furthermore, the significant dose × treatment interaction effect on LSAS was retained after controlling for main and moderating effects of the length of the prepost assessment interval (dose × treatment: = 9.07; P = .0025) and three known moderators of posttraining LSAS in this sample: age (dose × treatment: = 7.67; P = .0116), training location (dose × treatment: = 7.84; P = .0088), and LSAS rater (dose × treatment: = 8.80; P = .0030). Furthermore, when constricting the sample to studies that delivered ABM in the laboratory (n = 7 studies)-a group of studies where significant main effects of ABM on LSAS and AB scores were observed in our previous analyses-significant dose × treatment interaction effects were nevertheless retained for both LSAS (dose × treatment: = 13.76; P = .0011) and AB (dose × treatment: = 23.80; P = .0001).
Alternative explanations/confounds
In a subset of the data (n = 327; three "high" and three "low" dose studies) where raw dot-probe performance data were available, we assessed whether moderating effects of dose might be explained by decreased motivation or increased fatigue at posttest (which could be Performance across all dot-probe assessment trials at posttreatment RT: mean = 626.37 ms, mean of within-subject SD = 782.79 ms Error rate: mean = 2.6%, SD = 1.2, N studies = 3 RT: mean = 621.10 ms, mean of within-subject SD = 181.28 ms Error rate: mean = 3.7%, SD = 2.4, N studies = 3
TA B L E 2 Comparisons of high-and low-dose studies on possible other explanatory/confounding variables
Mean RT: t 4 = 0.12, P = .91 SD of RT: t 4 = 1.04, P = .36 Mean error rate: t 4 = 0.70, P = .52 LSAS, Liebowitz Social Anxiety Scale; RT, reaction time.
amplified by increasing doses of preceding training trials/repetitions).
For each participant at each assessment point (pre and posttest), this was quantified behaviorally across all dot-probe assessment trials as:
overall mean RT, standard deviation of RT, and error rate. There was no evidence that training dose (dichotomized or continuous) was related to any of these performance/motivation indices, either at posttest (P's > .36; Table 2 ) or expressed as a change score from pre-to posttest (P's > .293), and controlling for these performance variables did not alter the significance of any finding.
Studies with supraliminal presentation
Only one included study utilized subliminal presentation procedures (Maoz, Abend, Fox, Pine, & Bar-Haim, 2013) , while all other studies used supraliminal (i.e., above the threshold for conscious perception) presentations. Excluding this study from analysis maintained or strengthened all reported findings (LSAS: dichotomized dose × treatment = 9.42; P = .003; continuous dose × treatment = 0.0063; P = .01; AB: dichotomized dose × treatment = 44.32; P < .00005; continuous dose × treatment = 0.013; P = .0042).
DISCUSSION
Considerable research resources have been devoted over the last decade to the question of whether ABM, a low-cost, fully automated, mechanistic intervention has ameliorating effects on clinical anxiety.
Previous meta-analyses, including those using the present dataset, have suggested that ABM is indeed an efficacious treatment (Heeren et al., 2015; Linetzky, Pergamin-Hight, Pine, & Bar-Haim, 2015; Price, Wallace, et al., 2016) , yielding clinically significant improvements (e.g., is widely used and publically available) to the problem of social anxiety, suggesting that ABM can be delivered extremely efficiently [i.e., in as few as 768 trials delivered over four consecutive days (Heeren, Reese, McNally, & Philippot, 2012) ] without sacrificing clinical potency. However, it is important to note that all included studies offered repeated sessions of training, whereas previous meta-analyses have suggested that single-session training protocols are less effective (Beard et al., 2012; Hallion & Ruscio, 2011) , potentially due to the lack of critical between-session consolidation effects Abend et al., 2014) . The field has been previously left in the dark with respect to proper empirical guidance for this type of very basic intervention design decision. The counter-intuitive nature of the present findings suggests intuition may not be an adequate guide for such decision making, and strongly suggests the need for empirically derived guidelines.
Findings further suggest several avenues for continuing to refine and improve upon ABM's effects. One possible explanation for the observed pattern is that a larger dose of control conditions-which match active ABM on many salient features (e.g., repeated exposure to threat stimuli; completion of a cognitive task that encourages flexible or attentional allocation)-might have exhibited larger effects at higher doses, washing out effects of ABM in comparison to control. Indeed, these control conditions have sometimes been suggested to constitute useful training interventions themselves (Badura-Brack et al., 2015; Boettcher et al., 2013) via similar, but not identical, mechanisms-e.g., flexible attentional allocation in the context of threat and/or decreased avoidance of threat. However, here, the data suggested that ABM itself was also less beneficial in studies delivering a larger number of trials (Fig. 1) . The dosing effect did not appear to be due to differential passage of time, as the total duration of the experiments (i.e. the prepost assessment interval) was orthogonal to dose (Table 1 ) and did not reduce the effect when included as a covariate. Nor was there evidence that greater training doses increased fatigue or lowered task motivation (see Section 3.2). Thus, it may be that there is a "sweet spot" for the number of repetitions of the ABM paradigm that produces a clinically beneficial effect, potentially consistent with well-established findings in the perceptual discrimination literature suggesting that overrepetition can become detrimental to learning (Harris, Gliksberg, & Sagi, 2012; Mednick, Arman, & Boynton, 2005) . Furthermore, excessive repetition of a task that encourages constant avoidance of threat (i.e., attentional allocation away from threat) might "overcorrect" patterns of vigilance toward threat, paradoxically encouraging attentional rigidity, thereby reversing any beneficial effect that a lower, "weaker" dose would have had. This suggestion is consistent with the notion that rigid attentional preferences in either direction (toward or away from threat) may be detrimental (e.g., Price, Rosen, et al., 2015) , while the ability to flexibly allocate attention (e.g., based on context, current demands and goals) (Badura-Brack et al., 2015; Price et al., 2013) may represent an optimal cognitive state. Possibly, ABM might best achieve such flexibility with a smaller number of trials, when rigid patterns of vigilance to threat have just begun to shift, but prior to the firm instantiation of a new, rigid pattern of allocating attention away from threat.
Novel training paradigms could be designed to increase flexibility itself, e.g., through alternating trials or blocks of training either toward or away from threat, or through feedback-based attentional conditioning paradigms (Price, Greven, Siegle, Koster, & De Raedt, 2016) that could be designed to operationalize a goal state of attentional flexibility.
A meta-analytic approach cannot conclusively rule out alternative study-level parameters that may have covaried with dosing and explain the observed effect, given that dosing decisions will necessarily be made in the context of numerous other procedural variables that vary across studies. However, the effect on social anxiety was robust after controlling for previously identified moderators (participant age, training setting, LSAS rater) and for prepost assessment interval and motivation/fatigue-related behavioral indices, and dose did not appear to be confounded with these variables (Table 2) . Furthermore, the effect was present even among laboratory-based studies alone, a subset of ABM studies that has consistently shown robust clinical effects in meta-analyses (Heeren et al., 2015; Linetzky et al., 2015; Mogoaşe et al., 2014; Price, Wallace, et al., 2016) . Our findings stand in contrast to one previous, standard (study-level) metaanalysis in social anxiety (Heeren et al., 2015) , where significant moderating effects of dose on clinical anxiety symptoms could not be established. Furthermore, in a subset of previous meta-analyses, an increasing number of sessions/visits (Hakamata et al., 2010) or training trials within each session (but conversely, not the number of sessions) (Heeren et al., 2015) were associated with a larger decrease in AB following ABM. The most salient distinction is our use of raw patient-level and trial-level data, enabling standardized scoring and outlier rescaling procedures, previously shown to improve reliability (Price, Kuckertz, et al., 2015) , to be applied to quantify AB levels based on a uniform task (the dot-probe task), and enabling individual differences in LSAS and AB trajectories (one per participant) to be modeled rather than relying on group means and effect sizes (one per study) to represent all individuals in a given study. We also captured dose both within and across sessions concurrently by quantifying the total number of training trials delivered across all sessions. In light of our findings and these discrepancies within the literature, future dose-response studies, holding all other parameters constant, are urgently needed to conclusively delineate the impact of dosing.
Limitations
We were constrained by certain aspects of the available published datasets, including lack of follow-up data and poor reliability of RT measurements of AB, even when methods to improve stability are applied (Price, Kuckertz, et al., 2015) . Effect sizes were small, suggesting substantial variability in outcomes remained unexplained by the examined moderator, although moderators collectively identified across this and previous examinations (Price, Wallace, et al., 2016 ) may help to define a combination of relatively independent factors that together promote greater intervention benefit. Though the present pooled dataset represents a tenfold increase in sample size over the mean of previously published ABM trials, the number of contributing studies, and hence the variability in dosing across studies, was limited.
Present findings await verification in dosing studies holding all study parameters (other than dose) constant.
CONCLUSIONS
ABM has shown promise as a fully automated intervention for anxiety, but mixed findings have prompted considerable debate, suggesting that procedures must be iteratively refined to produce reliable clinical potential. Here we report paradoxical effects of one fundamental, yet poorly understood, factor-the dose (number of training trials) administered. The clinical significance of ABM shows much room for improvement (Price, Wallace, et al., 2016) . Further attention to the role of dosing may help to optimize its potential, and
to clarify the precise attentional mechanisms (e.g., flexibility vs. rigidity) that account for its effects. 
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